MA43767A - Anticorps non antagonistes dirigés contre la chaine alpha du domaine extracellulaire du récepteur de l'il-7 et leur utilisation dans le traitement du cancer - Google Patents
Anticorps non antagonistes dirigés contre la chaine alpha du domaine extracellulaire du récepteur de l'il-7 et leur utilisation dans le traitement du cancerInfo
- Publication number
- MA43767A MA43767A MA043767A MA43767A MA43767A MA 43767 A MA43767 A MA 43767A MA 043767 A MA043767 A MA 043767A MA 43767 A MA43767 A MA 43767A MA 43767 A MA43767 A MA 43767A
- Authority
- MA
- Morocco
- Prior art keywords
- receptor
- cancer
- treatment
- directed against
- extracellular domain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/624—Disulfide-stabilized antibody (dsFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662301271P | 2016-02-29 | 2016-02-29 | |
| PCT/IB2017/000293 WO2017149394A1 (fr) | 2016-02-29 | 2017-02-28 | Anticorps non antagonistes dirigés contre la chaine alpha du domaine extracellulaire du récepteur de l'il-7 et son utilisation dans le traitement du cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA43767A true MA43767A (fr) | 2019-01-09 |
| MA43767B1 MA43767B1 (fr) | 2019-08-30 |
Family
ID=58530580
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA43767A MA43767B1 (fr) | 2016-02-29 | 2017-02-28 | Anticorps non antagonistes dirigés contre la chaine alpha du domaine extracellulaire du récepteur de l'il-7 et leur utilisation dans le traitement du cancer |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US11230602B2 (fr) |
| EP (1) | EP3423496B1 (fr) |
| JP (1) | JP7053479B2 (fr) |
| KR (1) | KR20180118746A (fr) |
| CN (1) | CN109195987B (fr) |
| AU (1) | AU2017225495B2 (fr) |
| BR (1) | BR112018067479A2 (fr) |
| CA (1) | CA3014313A1 (fr) |
| CY (1) | CY1122072T1 (fr) |
| DK (1) | DK3423496T3 (fr) |
| ES (1) | ES2737307T3 (fr) |
| HR (1) | HRP20191445T1 (fr) |
| HU (1) | HUE045183T2 (fr) |
| IL (1) | IL261330B2 (fr) |
| LT (1) | LT3423496T (fr) |
| MA (1) | MA43767B1 (fr) |
| MD (1) | MD3423496T2 (fr) |
| ME (1) | ME03446B (fr) |
| PL (1) | PL3423496T3 (fr) |
| PT (1) | PT3423496T (fr) |
| RS (1) | RS59223B1 (fr) |
| SI (1) | SI3423496T1 (fr) |
| WO (1) | WO2017149394A1 (fr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2955196A1 (fr) | 2014-06-10 | 2015-12-16 | Effimune | Anticorps dirigés contre CD127 |
| US20200362300A1 (en) * | 2017-08-29 | 2020-11-19 | Ose Immunotherapeutics | Method and preparation for sorting out t effector cells using anti-cd127 antibodies for applications in cell therapy |
| AU2019265888A1 (en) * | 2018-05-10 | 2020-11-26 | Neuracle Science Co., Ltd. | Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof |
| CN114746445A (zh) * | 2019-06-28 | 2022-07-12 | 墨尔本大学 | 抑制或激活γδT细胞的方法 |
| CN110894237B (zh) * | 2019-12-05 | 2021-08-03 | 山东省分析测试中心 | 抗cd127的抗体、分泌该抗体的细胞株及其制备方法和应用 |
| WO2021222227A1 (fr) * | 2020-04-27 | 2021-11-04 | Memorial Sloan-Kettering Cancer Center | Récepteur antigénique chimérique ciblant cd127 et utilisation associée |
| EP4153631A1 (fr) * | 2020-05-18 | 2023-03-29 | Jumaa-Weinacht, Hassan | Composition pour le traitement de la leucémie lymphoblastique aiguë positive au chromosome philadelphie |
| CN113501878B (zh) * | 2021-02-03 | 2022-12-02 | 北京智仁美博生物科技有限公司 | 针对人tslp的多种抗体及其用途 |
| US20220389104A1 (en) * | 2021-05-28 | 2022-12-08 | Ose Immunotherapeutics | Method for Treating CD127-Positive Cancers by Administering an Anti-CD127 Agent |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| EP2032695B1 (fr) | 2006-05-31 | 2018-08-15 | The Regents of The University of California | Expression de cd127 inversement proportionnelle à foxp3 et fonction suppressive des tregs cd4+ |
| EP1930342B1 (fr) | 2006-12-04 | 2012-01-25 | Institut Pasteur | OB-fold utilisé en tant que base pour l'ingénierie de nouveaux liants spécifiques |
| GB0724051D0 (en) | 2007-12-08 | 2008-01-16 | Medical Res Council | Mutant proteins and methods for producing them |
| TW201018482A (en) | 2008-08-08 | 2010-05-16 | Glaxo Wellcome Mfg Pte Ltd | Novel treatment |
| WO2010085643A1 (fr) | 2009-01-22 | 2010-07-29 | University Of Miami | Ciblage de la signalisation il-7 à des fins de traitement de la sclérose en plaques et d'autres troubles dépendant de la signalisation il-7 |
| UA104663C2 (en) | 2010-01-28 | 2014-02-25 | Глаксо Груп Лимитед | Antibody binding to cd127 |
| AR080291A1 (es) * | 2010-02-24 | 2012-03-28 | Rinat Neuroscience Corp | Anticuerpos antagonistas anti receptor de il-7 y procedimientos |
| EP2583980A1 (fr) | 2011-10-19 | 2013-04-24 | Effimune | Anticorps dirigés contre la chaîne alpha du récepteur IL7, leur utilisation pour la préparation de candidats médicaments |
| US20150297310A1 (en) | 2014-04-17 | 2015-10-22 | Georgia Regents Research Institute, Inc. | Methods for selecting a treatment for cancer |
| EP2955196A1 (fr) * | 2014-06-10 | 2015-12-16 | Effimune | Anticorps dirigés contre CD127 |
-
2017
- 2017-02-28 US US16/080,572 patent/US11230602B2/en active Active
- 2017-02-28 EP EP17716593.3A patent/EP3423496B1/fr active Active
- 2017-02-28 CA CA3014313A patent/CA3014313A1/fr active Pending
- 2017-02-28 PT PT17716593T patent/PT3423496T/pt unknown
- 2017-02-28 JP JP2018545380A patent/JP7053479B2/ja active Active
- 2017-02-28 BR BR112018067479A patent/BR112018067479A2/pt unknown
- 2017-02-28 AU AU2017225495A patent/AU2017225495B2/en active Active
- 2017-02-28 KR KR1020187028377A patent/KR20180118746A/ko not_active Application Discontinuation
- 2017-02-28 DK DK17716593.3T patent/DK3423496T3/da active
- 2017-02-28 SI SI201730078T patent/SI3423496T1/sl unknown
- 2017-02-28 ME MEP-2019-215A patent/ME03446B/fr unknown
- 2017-02-28 MD MDE20190066T patent/MD3423496T2/ro not_active IP Right Cessation
- 2017-02-28 CN CN201780014099.2A patent/CN109195987B/zh active Active
- 2017-02-28 MA MA43767A patent/MA43767B1/fr unknown
- 2017-02-28 WO PCT/IB2017/000293 patent/WO2017149394A1/fr active Application Filing
- 2017-02-28 HU HUE17716593A patent/HUE045183T2/hu unknown
- 2017-02-28 IL IL261330A patent/IL261330B2/en unknown
- 2017-02-28 RS RSP20190987 patent/RS59223B1/sr unknown
- 2017-02-28 PL PL17716593T patent/PL3423496T3/pl unknown
- 2017-02-28 ES ES17716593T patent/ES2737307T3/es active Active
- 2017-02-28 LT LTEP17716593.3T patent/LT3423496T/lt unknown
-
2019
- 2019-08-09 HR HRP20191445 patent/HRP20191445T1/hr unknown
- 2019-08-23 CY CY20191100905T patent/CY1122072T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL3423496T3 (pl) | 2020-01-31 |
| CN109195987A (zh) | 2019-01-11 |
| IL261330B2 (en) | 2023-03-01 |
| HUE045183T2 (hu) | 2019-12-30 |
| ES2737307T3 (es) | 2020-01-13 |
| PT3423496T (pt) | 2019-09-05 |
| RS59223B1 (sr) | 2019-10-31 |
| MD3423496T2 (ro) | 2020-01-31 |
| CY1122072T1 (el) | 2020-11-25 |
| AU2017225495B2 (en) | 2024-05-09 |
| EP3423496A1 (fr) | 2019-01-09 |
| LT3423496T (lt) | 2019-09-25 |
| JP2019515648A (ja) | 2019-06-13 |
| EP3423496B1 (fr) | 2019-07-03 |
| IL261330B (en) | 2022-11-01 |
| KR20180118746A (ko) | 2018-10-31 |
| CA3014313A1 (fr) | 2017-09-08 |
| BR112018067479A2 (pt) | 2019-01-15 |
| DK3423496T3 (da) | 2019-08-19 |
| US20200308288A1 (en) | 2020-10-01 |
| IL261330A (en) | 2018-10-31 |
| HRP20191445T1 (hr) | 2019-11-15 |
| ME03446B (fr) | 2020-01-20 |
| CN109195987B (zh) | 2022-05-27 |
| AU2017225495A1 (en) | 2018-08-23 |
| US11230602B2 (en) | 2022-01-25 |
| WO2017149394A1 (fr) | 2017-09-08 |
| JP7053479B2 (ja) | 2022-04-12 |
| MA43767B1 (fr) | 2019-08-30 |
| SI3423496T1 (sl) | 2019-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA43767A (fr) | Anticorps non antagonistes dirigés contre la chaine alpha du domaine extracellulaire du récepteur de l'il-7 et leur utilisation dans le traitement du cancer | |
| FR23C1010I1 (fr) | Anticorps bispecifiques anti-ang-2/anti-vegf et leur utilisation dans le traitement des maladies vasculaires oculaires | |
| MA44776A (fr) | Anticorps anti-vista humain et leur utilisation | |
| FR23C1015I1 (fr) | Procédés de sélection d'une lignée de lymphocytes t et donneur de lignée de lymphocytes t pour thérapie cellulaire adoptive | |
| MA45122A (fr) | Inhibiteurs hétérocycliques de cbp/ep300 et leur utilisation dans le traitement du cancer | |
| MA44146A (fr) | Combinaison d'anticorps anti-pd-1 et d'anticorps bispécifiques anti-cd20/anti-cd3 pour traiter le cancer | |
| MA39960A (fr) | Composés imidazo[4,5c]quinoline-2-one et leur utilisation dans le traitement du cancer | |
| MA42243A (fr) | Anticorps de facteur xi et méthodes d'utilisation | |
| MA42043A (fr) | Anticorps anti-ox40 et procédés d'utilisation de ceux-ci | |
| MA47849A (fr) | Anticorps anti-gitr et leurs procédés d'utilisation | |
| MA51552A (fr) | Anticorps anti-ox40 et procédés d'utilisation | |
| WO2015031808A3 (fr) | Procédés de diagnostic et compositions pour le traitement d'un glioblastome | |
| TR201903840T4 (tr) | İnsan tamamlayıcı C5'e bağlanan polipeptitler. | |
| MA46085A (fr) | Dérivés d'imidazole et leur utilisation dans le traitement de maladies ou de cancers auto-immuns ou inflammatoires | |
| HK1246669A1 (zh) | 人血清白蛋白低分子量組分在疾病治療中的應用 | |
| MA47450A (fr) | Sulfinylpyridines et leur utilisation dans le traitement du cancer | |
| MA43361A (fr) | Composition pour le soin et la protection de cultures | |
| MA44762A (fr) | Sémaglutide utilisé dans le traitement de maladies cardiovasculaires | |
| FR2999428B1 (fr) | Chitine ou derives de chitine pour utilisation dans la prevention et/ou le traitement de parasitoses | |
| MA49884A (fr) | Composés imidazo[4,5-c]quinolin-2-one deutérés et leur utilisation dans le traitement du cancer | |
| MA40512A (fr) | Anticorps de l'angiopoïétine-like 4 et procédés d'utilisation correspondants | |
| FR3055548B1 (fr) | Utilisation de metabolites du tryptophane dans le traitement de l'atrophie musculaire | |
| HUE060882T2 (hu) | Naftiridinon-származékok és alkalmazásuk arrhytmia kezelésében | |
| MA41090A (fr) | Antagoniste de a2a faiblement dosé pour le traitement du tdah et de la maladie de parkinson | |
| PT3568397T (pt) | Compostos e a sua utilização no tratamento da esquistossomose |